A review of 6 placebo-controlled clinical trials with 1,134 complete participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) ended up connected to a better ordinary enhancement within the Ashworth scale for spasticity in various sclerosis sufferers as opposed with placebo,